---
schema_version: "secwatch.filing_event.v1"
accession: "0001562762-25-000006"
form_type: "8-K"
ticker: "GMED"
cik: "0001237831"
company_name: "GLOBUS MEDICAL INC"
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:17:14.838507+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Globus Medical prelim Q4 sales $657M (+6.6% YoY), FY24 $2.52B; guides FY25 rev $2.66-2.69B

## Summary
- Q4 2024 preliminary net sales ~$657M, up 6.6% as-reported vs Q4 2023; FY2024 ~$2.52B, up 60.6%.
- FY2025 revenue guidance $2.66-2.69B; fully diluted non-GAAP EPS $3.40-$3.50.
- CEO highlights record product launches and highest Enabling Technology placements post-NuVasive merger.
- Full Q4 and FY2024 results to be reported on February 20, 2025 after market close.

## SEC filing metadata
- accession: 0001562762-25-000006
- form_type: 8-K
- ticker: GMED
- cik: 0001237831
- company_name: GLOBUS MEDICAL INC
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/0001562762-25-000006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1237831/000156276225000006/gmed-20250108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001562762-25-000006
- JSON: https://secwatch.observer/filing/0001562762-25-000006.json
- Plain text: https://secwatch.observer/filing/0001562762-25-000006.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.